HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma by Contenti, J., Guo, Y., Larcher, M., Mirabal-Ortega, L., Rouleau, M., Irondelle, M., Tiroille, V., Mazzu, A., Duranton-Tanneur, V., Pedeutour, F., Ben-Sahra, I., Lago, C., Leva, G., Tiberi, L., Robert, G., Pouponnot, C., Bost, F., Mazure, N. M.

Get full text

Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S by Fanjat, Y., Barazzutti, H., Di Mauro, I., Tabary-Martin, L., Duranton-Tanneur, V., Gimet, S., Bérard, H., Pedeutour, F.

Get full text

HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma by Contenti, J, Guo, Y, Larcher, M, Mirabal-Ortega, L, Rouleau, M, Irondelle, M, Tiroille, V, Mazzu, A, Duranton-Tanneur, V, Pedeutour, F, Ben-Sahra, I, Lago, C, Leva, G, Tiberi, L, Robert, G, Pouponnot, C, Bost, Frédéric, Mazure, N M

Get full text

HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma by Contenti, J., Guo, Y., Larcher, M., Mirabal-Ortega, L., Rouleau, M., Irondelle, M., Tiroille, V., Mazzu, A., Duranton-Tanneur, V., Pedeutour, F., Ben-Sahra, I., Lago, C., Leva, G., Tiberi, L., Robert, G., Pouponnot, C., Bost, F., Mazure, Nathalie M

Get full text

Évaluation du statut mutationnel des gènes KRAS, NRAS, HRAS, BRAF et EGFR comme facteur prédictif de la réponse au traitement par cétuximab chez les patients atteints de carcinomes... by Picard, A., Duranton-Tanneur, V., Peyrade, F., Chamorey, E., Saudes, L., Cardot-Leccia, N., Sudaka, A., Kubiniek, V., Poissonnet, G., Michiels, J.-F., Lacour, J.-P., Passeron, T., Pedeutour, F., Montaudié, H.

Get full text